OQROGet OQRO Pro
Insider trade

Ultragenyx Pharmaceutical (RARE)CEO sold ~$414K

Emil D Kakkis, CEO at Ultragenyx Pharmaceutical, sold ~$414K of Ultragenyx Pharmaceutical shares.

~$414K
Approx. value · 8,273 sh @ $50.00
2.2M
Holds after · shares reported
Traded
Dec 10, 2024
Filed
Dec 11, 2024

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 10, 2024InsiderCFO sold ~$394K of RARE shares in the open market
  2. Dec 10, 2024 · this disclosureInsiderCEO sold ~$414K of RARE shares in the open market

What came next

  1. Dec 30, 2024InsiderCEO sold ~$495K of RARE shares in the open market
  2. Feb 27, 2025Insider · 1 personInsiders: 2 sales (~$128K)
  3. Feb 28, 2025InsiderCEO sold ~$1.06M of RARE shares in the open market
  4. Mar 3, 2025Insider · 7 peopleInsiders: 7 sales (~$5.5M)
  5. Mar 6, 2025InsiderCFO sold ~$72K of RARE shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Ultragenyx Pharmaceutical

For Ultragenyx Pharmaceutical, OQRO holds 5 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its RARE page.

Other recent filings by Emil D Kakkis, President & CEO

The full history of Emil D Kakkis, President & CEO is on the profile page.

How this filing works

Other disclosures at Ultragenyx Pharmaceutical

Everything OQRO holds on this company is on its RARE page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data